Understanding the Biology of Bone Metastases: Key to the Effective Treatment of Prostate Cancer
Open Access
- 15 March 2008
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 14 (6) , 1599-1602
Abstract
Advanced prostate cancer is dominated by bone-forming osseous metastases. Understanding the biology behind this striking clinical manifestation is the key to its effective treatment. A clinical trial using a bone-targeting radiopharmaceutical agent, strontium 89, combined with chemotherapy showed increased survival time among patients with progression of prostate cancer in bone, suggesting that therapeutic strategies focused on treating the tumor in bone are effective. We and others thus hypothesize that interactions between prostate cancer cells and the bone microenvironment play a role in the progression of prostate cancer in bone. Clinical trials and basic science investigations aiming to understand such interactions have been carried out in parallel. In the laboratory studies, human bone marrow specimens have been collected for identification of proteins involved in the bidirectional interactions between prostate cancer cells and bone. In addition, specimens from bone biopsies of the cancer lesions have been used to generate xenografts in animals to establish animal models for testing therapeutic strategies. Clinical trials using agents to inhibit the stromal-prostate cancer interactions (e.g., docetaxel/imatinib or thalidomide) have been done. Analyses of the specimens from these trials provided support of our hypothesis and future development of diagnosis and therapy strategies.Keywords
This publication has 16 references indexed in Scilit:
- Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacyProceedings of the National Academy of Sciences, 2007
- Platelet-Derived Growth Factor Receptor Inhibition and Chemotherapy for Castration-Resistant Prostate Cancer with Bone MetastasesClinical Cancer Research, 2007
- A Secreted Isoform of ErbB3 Promotes Osteonectin Expression in Bone and Enhances the Invasiveness of Prostate Cancer CellsCancer Research, 2007
- Initial Modulation of the Tumor Microenvironment Accounts for Thalidomide Activity in Prostate CancerClinical Cancer Research, 2007
- Targeting Platelet-Derived Growth Factor Receptor on Endothelial Cells of Multidrug-Resistant Prostate CancerJNCI: Journal of the National Cancer Institute, 2006
- Randomized Phase II Trial of Docetaxel Plus Thalidomide in Androgen-Independent Prostate CancerJournal of Clinical Oncology, 2004
- Activation of the Platelet-Derived Growth Factor-Receptor Enhances Survival of Murine Bone Endothelial CellsCancer Research, 2004
- Up‐regulation of MDA‐BF‐1, a secreted isoform of ErbB3, in metastatic prostate cancer cells and activated osteoblasts in bone marrowThe Journal of Pathology, 2004
- Roles for Hedgehog signaling in androgen production and prostate ductal morphogenesisDevelopmental Biology, 2004
- Effects of platelet‐derived growth factor on bone formation in vitroJournal of Cellular Physiology, 1989